NCT02551744

Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers

Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 101 (actual)
• Sponsor: Kaohsiung Veterans General Hospital. · Academic / Other
• Sex: All
• Age: 20 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.

Detailed description

The aims of the randomized double-blind comparison study are to compare the efficacy of Proton Pump Inhibitor and H2 receptor antagonist for the prevention of recurrent peptic ulcers in thienopyridine users. We plan to enroll 334 thienopyridine (clopidogrel or ticlopidine) users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) pantoprazole (40 mg qd) or (2) famotidine (40 mg qd) for 6 months.The ulcer recurrence rate between the treatment groups will be compared.

Conditions

• Peptic Ulcer

Interventions

Type	Name	Description
DRUG	histamine-2 receptor antagonist group	famotidine tab 40 mg qd for 6 months.
DRUG	proton pump inhibitor group	pantoprazole tab 40 mg qd for 6 months.

Timeline

• Start date: 2012-07-01
• Primary completion: 2018-07-01
• Completion: 2018-07-01
• First posted: 2015-09-16
• Last updated: 2019-08-08
• Results posted: 2019-08-08

Locations

1 site across 1 country: Taiwan